Diabetes Care Market - Fondation The Ark...2014/06/06 · Insulin pens & syringes Patients...

Overview of the Diabetes

Care Market Journée e-Health

Gian Piero Reverberi

Diabetes is a very large and growing problem worldwide

Many pharmacological innovations have been and will be introduced in

the future to address the needs of patients with Diabetes

Despite these innovations, Insulin will remain an important ammunition

in the hands of HCP to treat patients with diabetes

In addition to the significant pharmacological innovations, innovative

delivery systems and devices dramatically helped patients with

diabetes managing their life and their disease.

Significant future opportunties lie in the development of technologies

that can continue simplifying patients life, while supporting the

electronic transfer and elaboration of information for an integrated

disease management system

Executive Summary

Number of people with diabetes by region, 2013

Source: international diabetes federation

Diabetes is a huge and growing problem,

and the costs to society are high and escalating.

Prevalence of overweight and obesity in seleced countries

Sassi, F et al. 2009 The obesity Epidemic: analysis of past and projected

Future trends in Selected OECD Countries


Many pharmacological innovations have been and will be

introduced in the future to address the needs of patients with

Diabetes










Executive Summary

Evolution of Diabetes treatment for Type 2 patients

Time Time

Animal Insulin

Human Insulin

Insulin Analogs

GLP1 B cells insulin secretion

Sulfonylurea

Metformin

Alfa glucosidade inhibitors

TZD (Insulin resistance)

DPP IV Inhibitors Enzyme responsible

for degradation of GLP1

SGL 2 Inhibitors Prevent Reabsorption

of filtered glucose

47%

38%

7%

0%

7%

36%

33%

12%

16%

3%

Insulin

DPP IV Inhibitors

GLP 1

SGL 2 Inhibitors

TZD

2013

17 million Patients 2022

26 million Patients

Evolution of treatment in USA, EU5 and Japan – 2013 - 2022 (Sulfonylurea, Metformin and Alfa glucosidate inhibitor excluded)

Datamonitor Healthcare forecast - 2014




Despite these innovations, Insulin will remain an important

ammunition in the hands of HCP to treat patients with diabetes


delivery systems dramatically helped patients with diabetes managing

their life and their disease.





Executive Summary

67%

8%

25%

0%

70%

6%

17%

8%

Basal

Mix

Rapid

Insulin+GLP1

Evolution of Insulin treatment in USA, EU5 and Japan – 2013 - 2022 N. Of Patients

2013

8 million Patients


2022

10 million Patients






In addition to the significant pharmacological innovations,

innovative delivery systems and devices dramatically helped

patients with diabetes managing their life and their disease.





Executive Summary

Innovation in Insulin delivery









Significant future opportunties lie in the development of

technologies that can continue simplifying patients life, while

supporting the electronic transfer and elaboration of information

for an integrated disease management system

Executive Summary

“….the use of modern information and

communication technologies to meet needs of

citizens, patients, healthcare professionals,

healthcare providers, as well as policy makers"

http://europa.eu/

European Community definition of E-health

Information for

patients

Communication

among patients

Information from

patients to

stakeholders

Communication

between patients

and

stakeholders

Greater patient demand for

more interactive, accessible,

high quality information

• Consumers are increasingly

leveraging the internet as a

source of information

18% CAGR from ‘98-’10

in amount of adults who

often look online for health

information

• Greater amount of health care

information is available to

consumers

• Patient-to-patient

information increasing Professional-to-patient

information increasing

• Online community for people with

life changing conditions

• More than 250’000 members

• More than 2000 conditions

• Platform for collecting and sharing

detailed real world, outcome-

based patient data

• Leading health portal in the US

• More than 80 million unique visitors per month

• Offers health advice, symptom checklist, drug information and community

• Remote monitoring

programs and

technologies

• Bluetooth devices

• Smartphone applications

• Blood pressure cuffs send

readings directly to your PC

• Eg: Blood glucose meter

seamlessly connects to the

iPhone

Examples of information and communication among HC

players

Technology is changing the way healthcare is delivered

Smartphone

applications

Computing

power

Connectivity

Remote

monitoring

and

Management

Data analytics

Electronic

records and

coding

Technological innovation Healthcare Delivery

Diabetes Care

Disease management

Systems

Health information exchange in current diabetes

care devices

Connectivity available No connectivity Connectivity available

100 % use Lancing devices – Glucose meters

95% use Insulin pens & syringes

Patients diagnosed with diabetes Patients on Insulin

5% use insulin pumps

http://www.google.ch/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&cad=rja&uact=8&docid=uJMBnjbDxLFKfM&tbnid=QzIlsC7BZkkvCM:&ved=0CAUQjRw&url=http://www.ebay.ca/sch/Lancets-/72875/i.html&ei=-iyPU-apIIffOrqxgNgL&bvm=bv.68235269,d.bGQ&psig=AFQjCNE4GINiIQYCTh8Hktm8gg92DTxxNg&ust=1401978436394546













Executive Summary

Back up

0

5

10

15

20

25

0

1

2

3

4

5

6

7

8

1958 62 66 70 74 78 82 86 90 94 98 02 06 10

Nu

mb

er

with

Dia

be

tes (

Mill

ion

s)

Perc

enta

ge w

ith D

iabete

s

Year

Percentage with Diabetes

Number with Diabetes

Number and Percentage of U.S. Population with Diagnosed Diabetes,

1958–2010

CDC’s Division of Diabetes Translation. National Diabetes Surveillance System available at http://www.cdc.gov/diabetes/statistics

Age-adjusted Prevalence of Obesity and Diagnosed

Diabetes Among U.S. Adults Aged 18 Years or Older

Obesity (BMI ≥30 kg/m2)

Diabetes

1994

1994

2000

2000

No Data <14.0% 14.0%–17.9% 18.0%–21.9% 22.0%–25.9% 26.0%

No Data <4.5% 4.5%–5.9% 6.0%–7.4% 7.5%–8.9% >9.0%

CDC’s Division of Diabetes Translation. National Diabetes Surveillance System available at http://www.cdc.gov/diabetes/statistics

2010

2010

Diabetes has become an epidemic, primarily driven by

lifestyle changes (projections appear conservative)

International Diabetes Foundation: Diabetes Atlas

0

2'000

4'000

6'000

8'000

10'000

12'000

14'000

16'000

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

Insulin

DPP IV Inhibitors

GLP 1

SGL 2 Inhibitors

TZD

Expected Revenues of Diabetes care treatment in USA, EU5 and Japan (Sulfs, Matformin and Alfa glucosidate inhibitor excluded)

USD Millions


0

1'000'000

2'000'000

3'000'000

4'000'000

5'000'000

6'000'000

7'000'000

8'000'000

9'000'000

10'000'000

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

Insulin

DPP IV Inhibitors

GLP 1

SGL 2 Inhibitors

TZD

Expected number of patients on Diabetes care treatment in USA, EU5 and Japan (Sulfs, Matformin and Alfa glucosidate inhibitor excluded)


0

2'000

4'000

6'000

8'000

10'000

12'000

14'000

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

Basal

Mix

Rapid

Insulin+GLP1

Forecasted Insulin revenues in USA, EU5 and Japan between 2013 and 2022 USD Millions


70%

12%

18%

0%

69%

6%

7%

19%

Basal

Mix

Rapid

Insulin+GLP1

Evolution of revenues of different forms of insulins in USA, EU5 and Japan

2013 – 2022

USD Million


0

1'000'000

2'000'000

3'000'000

4'000'000

5'000'000

6'000'000

7'000'000

8'000'000

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022

Basal

Mix

Rapid

Insulin+GLP1

Expected number of patients on different forms of Insulin in USA, EU5

and Japan


Diabetes Care Market - Fondation The Ark...2014/06/06 · Insulin pens & syringes Patients...

Documents

Transcript of Diabetes Care Market - Fondation The Ark...2014/06/06 · Insulin pens & syringes Patients...